How to Export Pharmaceutical Products and Medicines to North America (USA & Canada) and Latin American Countries: A Detailed Stepwise Legal and Procedural Guide

The pharmaceutical export sector constitutes one of the most regulated and compliance-driven industries in international trade. Export of medicines, pharmaceutical formulations, APIs, biological products, nutraceuticals and healthcare products to North America, particularly the United States and Canada, as well as Latin American countries, requires strict adherence to Indian export laws, foreign trade regulations, customs procedures, international quality standards, foreign exchange laws and importing country regulations.

The pharmaceutical industry in India is globally recognized for generic medicines, vaccines, APIs and affordable healthcare products. However, pharmaceutical exports involve multilayer regulatory compliances including licensing, registration, documentation, customs clearance, product approvals, shipping compliance, foreign exchange realization and export incentive declarations.

1. Constitution of Business Entity

The first step for pharmaceutical exports is establishment of a valid legal entity. The exporter may operate as:

• Proprietorship;
• Partnership Firm;
• LLP;
• Private Limited Company; or
• Public Limited Company.

The entity should obtain:

• PAN;
• TAN;
• Current account with AD Bank;
• GST Registration; and
• Drug manufacturing or trading licences under the Drugs and Cosmetics Act, 1940.

2. Import Export Code (IEC)

No person can export goods from India without obtaining Import Export Code (IEC) under the Foreign Trade (Development and Regulation) Act, 1992.

IEC is issued electronically by the Director General of Foreign Trade (DGFT). Application is filed online with:

• PAN;
• Aadhaar;
• Bank certificate/cancelled cheque;
• Address proof; and
• DSC/e-signature.

IEC is mandatory for:

• Customs clearance;
• Shipping bill filing;
• FEMA compliances;
• Realization of export proceeds; and
• DGFT benefits.

3. GST Registration and LUT/Bond

GST registration is compulsory for exporters. Pharmaceutical exports are treated as 'Zero Rated Supplies' under Section 16 of the IGST Act.

The exporter may export:

• Under Bond/LUT without payment of IGST; or
• On payment of IGST and claim refund later.

Letter of Undertaking (LUT) should be filed annually on the GST portal to avoid blockage of working capital.

4. Drug Manufacturing and Export Licences

Pharmaceutical exports require:

• Manufacturing Licence;
• WHO-GMP Certification;
• COPP (Certificate of Pharmaceutical Product);
• Product Registration Certificates;
• FDA/Health Canada approvals wherever applicable.

Exporters must comply with:

• Drugs and Cosmetics Act, 1940;
• NDPS Act (if narcotic substances involved);
• CDSCO guidelines; and
• Country-specific pharmaceutical regulations.

5. Registration with Pharmexcil

Exporters should obtain registration with the Pharmaceutical Export Promotion Council of India (Pharmexcil), functioning under the Ministry of Commerce.

RCMC (Registration-Cum-Membership Certificate) is required for:

• DGFT export benefits;
• International trade facilitation;
• Trade fairs;
• Export promotion schemes.

6. Product Registration in USA, Canada and Latin America

USA

Exports to the USA require compliance with:

• US FDA registration;
• Drug Master File (DMF);
• ANDA approvals;
• US labeling standards;
• cGMP compliance.

Manufacturing facilities may be inspected by US FDA authorities.

Canada

Exports to Canada require:

• Health Canada approvals;
• Drug Establishment Licence;
• Product registration;
• Bilingual labeling requirements.

Latin America

Countries such as Brazil, Mexico, Chile, Colombia and Peru require:

• Country-specific registration;
• Local authorized representative;
• Product dossiers;
• Stability studies;
• Pharmacovigilance compliance.

7. Product Classification and HSN

Correct classification of pharmaceutical products under Customs Tariff is essential.

Generally:

• Medicaments fall under Chapter 30;
• APIs under specific tariff headings;
• Vaccines and biological products under separate headings.

Incorrect classification may result in:

• Customs disputes;
• Penalties;
• Wrong export incentives.

8. Product Valuation

Export valuation should comply with:

• Customs Valuation Rules;
• FEMA regulations;
• Transfer Pricing provisions (for related party exports).

Invoice value must represent true transaction value. Under-invoicing and over-invoicing may attract investigation under:

• FEMA;
• Customs Act;
• PMLA.

9. INCOTERMS

Selection of INCOTERMS is crucial in pharmaceutical exports.

Common INCOTERMS include:

• FOB;
• CIF;
• CFR;
• DDP;
• FCA.

INCOTERMS determine:

• Risk transfer;
• Freight liability;
• Insurance obligations;
• Delivery responsibilities.

For pharmaceutical exports, CIF and CIP are commonly used due to insurance sensitivity.

10. Export Contracts and Documentation

Export agreements should include:

• Product specifications;
• Stability requirements;
• Packaging standards;
• Delivery schedules;
• INCOTERMS;
• Arbitration clauses;
• Governing law;
• Payment terms.

Key export documents include:

• Commercial Invoice;
• Packing List;
• Purchase Order;
• Certificate of Origin;
• COA (Certificate of Analysis);
• MSDS;
• Insurance Certificate;
• Bill of Lading/AWB;
• Export Declaration Forms.

11. Customs Broker and Logistics

Appointment of a licensed Customs Broker facilitates:

• Shipping Bill filing;
• Customs examination;
• Documentation;
• Port coordination.

Temperature-controlled logistics are essential for sensitive medicines.

Cold chain compliance must be ensured for:

• Vaccines;
• Injectables;
• Biologics.

12. Factory Stuffing and Self-Sealing

Exporters may opt for:

• Factory stuffing;
• Self-sealing;
• Self-certification.

Containers may be stuffed at factory premises under customs supervision or self-sealing procedures subject to regulatory norms.

Benefits include:

• Faster clearance;
• Reduced port congestion;
• Better cargo security.

13. Authorized Economic Operator (AEO)

Pharmaceutical exporters should obtain AEO certification from Customs.

Benefits include:

• Reduced examination;
• Faster clearance;
• Priority treatment;
• Deferred duty benefits;
• International recognition.

AEO status significantly improves export efficiency for pharmaceutical companies.

14. Shipping Bill (S/B)

Shipping Bill is the principal export document filed electronically through ICEGATE.

Types include:

• Free Shipping Bill;
• Drawback Shipping Bill;
• IGST Refund Shipping Bill;
• EPCG/Advance Authorization Shipping Bill.

Shipping Bill should contain:

• Correct IEC;
• GSTIN;
• HSN;
• FOB value;
• Scheme declarations;
• LUT details.

Incorrect declarations may block export incentives.

15. Export Promotion Scheme Declarations

Exporters may avail:

• RoDTEP;
• Duty Drawback;
• Advance Authorization;
• EPCG Scheme.

Appropriate declarations must be made in the Shipping Bill itself.

Failure to declare at export stage may result in denial of benefits.

16. Customs Clearance Procedure

The customs clearance process includes:

1. Preparation of export documents;
2. Shipping Bill filing;
3. Assessment by Customs;
4. Examination;
5. Let Export Order (LEO);
6. Loading of cargo;
7. Departure of vessel/aircraft.

Customs may conduct:

• Documentary verification;
• Physical examination;
• Sampling for laboratory testing.

Pharmaceutical exports are often subject to strict scrutiny due to health and safety considerations.

17. Marine Insurance

Marine insurance is essential to protect against:

• Transit damage;
• Theft;
• Temperature variation;
• Cargo loss.

Insurance policies generally include:

• Institute Cargo Clauses;
• Cold chain coverage;
• Product contamination risks.

ECGC policies may also supplement commercial insurance.

18. ECGC Protection

Export Credit Guarantee Corporation of India (ECGC) provides insurance cover against:

• Buyer default;
• Political risks;
• Exchange restrictions;
• Insolvency of foreign buyers.

Pharmaceutical exports to emerging Latin American markets may involve significant payment risks, making ECGC cover highly advisable.

19. FEMA Compliance and Realization of Export Proceeds

Export proceeds must be realized within timelines prescribed under FEMA and RBI regulations.

Currently, export proceeds are generally required to be realized within nine months from date of export unless extended.

Payment methods include:

• Advance payment;
• Letter of Credit;
• DA/DP terms;
• Wire transfer.

Non-realization may attract:

• FEMA penalties;
• RBI reporting;
• DGFT action.

20. EDPMS Monitoring

Exports are monitored through Export Data Processing and Monitoring System (EDPMS).

Shipping Bills are matched with:

• Bank realization data;
• e-BRC;
• Foreign inward remittances.

Mismatch in EDPMS may block:

• GST refunds;
• DGFT benefits;
• Future exports.

21. Bank Realization Certificate (BRC/e-BRC)

After receipt of export proceeds, the Authorized Dealer Bank issues e-BRC.

e-BRC serves as proof of:

• Export realization;
• FEMA compliance;
• DGFT incentive eligibility.

It is critical for:

• RoDTEP;
• Drawback;
• Export benefits.

22. GST Refund Mechanism

Exporters can claim:

• Refund of unutilized ITC; or
• Refund of IGST paid on exports.

Refund application is filed in Form GST RFD-01.

Necessary documentation includes:

• Shipping Bills;
• BRC;
• LUT;
• GSTR-1;
• GSTR-3B.

Mismatch between GST returns and customs data may delay refunds.

23. Quality Compliance and Packaging

Pharmaceutical exports require:

• Tamper-proof packaging;
• Batch traceability;
• Stability compliance;
• Serialization requirements;
• Child-resistant packaging.

North American markets impose stringent labeling and pharmacovigilance standards.

24. Anti-Counterfeiting Compliance

Many importing countries require:

• Barcode tracking;
• Serialization;
• Supply chain authentication.

Failure may result in seizure of goods abroad.

25. Intellectual Property and Trademark Protection

Exporters should register:

• Brand names;
• Trademarks;
• Patents where applicable.

Trademark disputes in foreign jurisdictions can lead to detention of consignments.

26. Common Compliance Risks

Major risks in pharma exports include:

• Misdeclaration;
• Expired products;
• Regulatory non-compliance;
• Labeling defects;
• FEMA violations;
• GST mismatch;
• Delayed realization;
• Temperature excursions.

Strong compliance systems are therefore essential.

Conclusion

Export of pharmaceutical products and medicines to the USA, Canada and Latin American countries is a highly regulated but commercially rewarding business activity. Successful pharmaceutical exporting requires synchronized compliance under GST laws, FEMA regulations, DGFT provisions, Customs procedures, CDSCO requirements, foreign regulatory approvals, logistics compliance and export incentive frameworks.

From obtaining IEC and GST registration to filing Shipping Bills, ensuring product registrations, obtaining ECGC cover, managing EDPMS reconciliation and claiming GST refunds, every stage requires meticulous legal and procedural adherence. Pharmaceutical exporters must therefore adopt a robust compliance-driven approach integrating customs law, foreign trade policy, banking regulations, quality standards and international trade practices to ensure smooth and sustainable export operations.

***